{"groups":[{"description":"Patients receive veliparib PO BID on days 1-21 and topotecan hydrochloride IV continuously over 24 hours and carboplatin IV continuously over 24 hours on days 3-7. Treatment repeats every 28-63 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.\n\nCarboplatin: Given IV\n\nTopotecan: Given IV\n\nTopotecan Hydrochloride: Given IV\n\nVeliparib: Given PO","id":"FG000","title":"Arm A (Veliparib, Topotecan Hydrochloride, Carboplatin)"},{"description":"Patients receive topotecan hydrochloride IV continuously over 24 hours and carboplatin IV continuously over 24 hours on days 1-5. Treatment repeats every 28-63 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.\n\nCarboplatin: Given IV\n\nTopotecan: Given IV\n\nTopotecan Hydrochloride: Given IV","id":"FG001","title":"Arm B (Topotecan Hydrochloride, Carboplatin)"}],"periods":[{"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"16"},{"groupId":"FG001","numSubjects":"9"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"16"},{"groupId":"FG001","numSubjects":"9"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}]}